nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—Cholecalciferol—Calcitriol—osteoporosis	0.258	1	CiPCiCtD
Paricalcitol—VDR—osteoporosis	0.0849	1	CbGaD
Paricalcitol—Ergocalciferol—osteoporosis	0.0727	0.351	CrCtD
Paricalcitol—Calcitriol—osteoporosis	0.0727	0.351	CrCtD
Paricalcitol—Cholecalciferol—osteoporosis	0.0618	0.298	CrCtD
Paricalcitol—chronic kidney failure—Calcium Acetate—osteoporosis	0.0546	0.416	CpDpCtD
Paricalcitol—chronic kidney failure—Calcitriol—osteoporosis	0.0414	0.315	CpDpCtD
Paricalcitol—CYP24A1—Calcitriol—osteoporosis	0.0354	0.264	CbGbCtD
Paricalcitol—chronic kidney failure—Cholecalciferol—osteoporosis	0.0352	0.268	CpDpCtD
Paricalcitol—CYP24A1—Ergocalciferol—osteoporosis	0.0283	0.211	CbGbCtD
Paricalcitol—VDR—Calcitriol—osteoporosis	0.0281	0.209	CbGbCtD
Paricalcitol—VDR—Ergocalciferol—osteoporosis	0.0225	0.167	CbGbCtD
Paricalcitol—VDR—Cholecalciferol—osteoporosis	0.0145	0.108	CbGbCtD
Paricalcitol—Calcidiol—Calcitriol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Calcidiol—Ergocalciferol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Alfacalcidol—Calcitriol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Ergocalciferol—Calcitriol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Cholecalciferol—Ergocalciferol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Calcitriol—Ergocalciferol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Dihydrotachysterol—Calcitriol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Dihydrotachysterol—Ergocalciferol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Cholecalciferol—Calcitriol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Calcipotriol—Ergocalciferol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Alfacalcidol—Ergocalciferol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Calcipotriol—Calcitriol—osteoporosis	0.00816	0.0585	CrCrCtD
Paricalcitol—Alfacalcidol—Cholecalciferol—osteoporosis	0.00694	0.0497	CrCrCtD
Paricalcitol—Calcitriol—Cholecalciferol—osteoporosis	0.00694	0.0497	CrCrCtD
Paricalcitol—Ergocalciferol—Cholecalciferol—osteoporosis	0.00694	0.0497	CrCrCtD
Paricalcitol—Dihydrotachysterol—Cholecalciferol—osteoporosis	0.00694	0.0497	CrCrCtD
Paricalcitol—Calcipotriol—Cholecalciferol—osteoporosis	0.00694	0.0497	CrCrCtD
Paricalcitol—Calcidiol—Cholecalciferol—osteoporosis	0.00694	0.0497	CrCrCtD
Paricalcitol—VDR—periosteum—osteoporosis	0.00149	0.347	CbGeAlD
Paricalcitol—VDR—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00134	0.142	CbGpPWpGaD
Paricalcitol—VDR—vertebral column—osteoporosis	0.00123	0.287	CbGeAlD
Paricalcitol—VDR—parathyroid gland—osteoporosis	0.00119	0.278	CbGeAlD
Paricalcitol—CYP3A4—Estropipate—osteoporosis	0.001	0.00747	CbGbCtD
Paricalcitol—CYP3A4—Calcitriol—osteoporosis	0.001	0.00747	CbGbCtD
Paricalcitol—CYP24A1—Vitamin D Metabolism—CYP27A1—osteoporosis	0.000853	0.0903	CbGpPWpGaD
Paricalcitol—CYP3A4—Ergocalciferol—osteoporosis	0.000802	0.00597	CbGbCtD
Paricalcitol—VDR—Vitamin D Metabolism—CYP27A1—osteoporosis	0.000715	0.0756	CbGpPWpGaD
Paricalcitol—CYP24A1—Vitamin D Metabolism—PTH—osteoporosis	0.000705	0.0747	CbGpPWpGaD
Paricalcitol—CYP3A4—Raloxifene—osteoporosis	0.000669	0.00498	CbGbCtD
Paricalcitol—CYP3A4—Ethinyl Estradiol—osteoporosis	0.000646	0.00481	CbGbCtD
Paricalcitol—VDR—Vitamin D Metabolism—PTH—osteoporosis	0.000591	0.0626	CbGpPWpGaD
Paricalcitol—CYP3A4—Cholecalciferol—osteoporosis	0.000517	0.00385	CbGbCtD
Paricalcitol—CYP3A4—Conjugated Estrogens—osteoporosis	0.000474	0.00353	CbGbCtD
Paricalcitol—CYP3A4—Estradiol—osteoporosis	0.000416	0.0031	CbGbCtD
Paricalcitol—CYP24A1—Vitamin D Metabolism—VDR—osteoporosis	0.000392	0.0414	CbGpPWpGaD
Paricalcitol—Ergocalciferol—CYP27A1—osteoporosis	0.000231	0.214	CrCbGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.000208	0.022	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000203	0.0215	CbGpPWpGaD
Paricalcitol—VDR—uterus—osteoporosis	0.000203	0.0474	CbGeAlD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000201	0.0212	CbGpPWpGaD
Paricalcitol—Cholecalciferol—CYP27A1—osteoporosis	0.000175	0.162	CrCbGaD
Paricalcitol—VDR—bone marrow—osteoporosis	0.000172	0.0402	CbGeAlD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—CYP19A1—osteoporosis	0.000172	0.0182	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000165	0.0175	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—ESR2—osteoporosis	0.000163	0.0173	CbGpPWpGaD
Paricalcitol—Dihydrotachysterol—VDR—osteoporosis	0.000156	0.145	CrCbGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CYP19A1—osteoporosis	0.000148	0.0157	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000147	0.0156	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—ESR2—osteoporosis	0.000142	0.015	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.000112	0.0119	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—COL1A2—osteoporosis	0.000112	0.0118	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000107	0.0113	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000105	0.0112	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—POMC—osteoporosis	0.000104	0.011	CbGpPWpGaD
Paricalcitol—Alfacalcidol—VDR—osteoporosis	0.0001	0.0932	CrCbGaD
Paricalcitol—Calcidiol—VDR—osteoporosis	0.0001	0.0932	CrCbGaD
Paricalcitol—Calcipotriol—VDR—osteoporosis	0.0001	0.0932	CrCbGaD
Paricalcitol—Calcitriol—VDR—osteoporosis	8.95e-05	0.083	CrCbGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP27A1—osteoporosis	8.76e-05	0.00927	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	8.66e-05	0.00917	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP27A1—osteoporosis	8.64e-05	0.00914	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—ESR1—osteoporosis	8.62e-05	0.00912	CbGpPWpGaD
Paricalcitol—Ergocalciferol—VDR—osteoporosis	7.16e-05	0.0664	CrCbGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP27A1—osteoporosis	7e-05	0.00741	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP27A1—osteoporosis	6.91e-05	0.00731	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—ESR1—osteoporosis	6.81e-05	0.00721	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—DKK1—osteoporosis	6.81e-05	0.00721	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.42e-05	0.0068	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	6.06e-05	0.00641	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	5.86e-05	0.0062	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	5.66e-05	0.00599	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	5.55e-05	0.00588	CbGpPWpGaD
Paricalcitol—Cholecalciferol—VDR—osteoporosis	5.42e-05	0.0503	CrCbGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.21e-05	0.00551	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoporosis	4.71e-05	0.00499	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	4.7e-05	0.00498	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP19A1—osteoporosis	4.6e-05	0.00487	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP19A1—osteoporosis	4.54e-05	0.0048	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	4.32e-05	0.00457	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	4.21e-05	0.00445	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—GPX1—osteoporosis	3.7e-05	0.00392	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP19A1—osteoporosis	3.68e-05	0.00389	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	3.66e-05	0.00387	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP19A1—osteoporosis	3.63e-05	0.00384	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—SPP1—osteoporosis	3.59e-05	0.0038	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—AGER—osteoporosis	3.44e-05	0.00364	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	3.42e-05	0.00362	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.36e-05	0.00356	CbGpPWpGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	3.32e-05	0.00352	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.86e-05	0.00303	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—POMC—osteoporosis	2.77e-05	0.00293	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	2.64e-05	0.00279	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—FDPS—osteoporosis	2.61e-05	0.00276	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PKM—osteoporosis	2.61e-05	0.00276	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	2.6e-05	0.00276	CbGpPWpGaD
Paricalcitol—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	2.49e-05	0.00263	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PGLS—osteoporosis	2.47e-05	0.00262	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GPD2—osteoporosis	2.47e-05	0.00262	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	2.45e-05	0.00259	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—U2AF1—osteoporosis	2.44e-05	0.00258	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ATIC—osteoporosis	2.26e-05	0.00239	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PNP—osteoporosis	2.26e-05	0.00239	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—POMC—osteoporosis	2.21e-05	0.00234	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	2.14e-05	0.00226	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PKM—osteoporosis	2.08e-05	0.00221	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—FDPS—osteoporosis	2.08e-05	0.00221	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GPD2—osteoporosis	1.98e-05	0.00209	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PGLS—osteoporosis	1.98e-05	0.00209	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—ESR2—osteoporosis	1.94e-05	0.00205	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—OXCT1—osteoporosis	1.92e-05	0.00203	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CA2—osteoporosis	1.92e-05	0.00203	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	1.91e-05	0.00202	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—MGLL—osteoporosis	1.87e-05	0.00198	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—RPL24—osteoporosis	1.81e-05	0.00192	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PNP—osteoporosis	1.81e-05	0.00191	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ATIC—osteoporosis	1.81e-05	0.00191	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.77e-05	0.00187	CbGpPWpGaD
Paricalcitol—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	1.71e-05	0.00181	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—IDH2—osteoporosis	1.59e-05	0.00169	CbGpPWpGaD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	1.58e-05	0.000517	CcSEcCtD
Paricalcitol—Paraesthesia—Risedronate—osteoporosis	1.58e-05	0.000517	CcSEcCtD
Paricalcitol—Pruritus—Estropipate—osteoporosis	1.57e-05	0.000515	CcSEcCtD
Paricalcitol—Discomfort—Zoledronate—osteoporosis	1.57e-05	0.000515	CcSEcCtD
Paricalcitol—Asthenia—Alendronate—osteoporosis	1.57e-05	0.000514	CcSEcCtD
Paricalcitol—Hypersensitivity—Ibandronate—osteoporosis	1.57e-05	0.000514	CcSEcCtD
Paricalcitol—Cough—Conjugated Estrogens—osteoporosis	1.57e-05	0.000514	CcSEcCtD
Paricalcitol—Dyspnoea—Risedronate—osteoporosis	1.56e-05	0.000513	CcSEcCtD
Paricalcitol—Hypotension—Pamidronate—osteoporosis	1.56e-05	0.000511	CcSEcCtD
Paricalcitol—Dry mouth—Zoledronate—osteoporosis	1.55e-05	0.00051	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	1.55e-05	0.000509	CcSEcCtD
Paricalcitol—Fatigue—Ethinyl Estradiol—osteoporosis	1.55e-05	0.000509	CcSEcCtD
Paricalcitol—Pruritus—Alendronate—osteoporosis	1.55e-05	0.000507	CcSEcCtD
Paricalcitol—Dyspepsia—Risedronate—osteoporosis	1.54e-05	0.000506	CcSEcCtD
Paricalcitol—Eye disorder—Estradiol—osteoporosis	1.54e-05	0.000506	CcSEcCtD
Paricalcitol—Constipation—Ethinyl Estradiol—osteoporosis	1.54e-05	0.000505	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CA2—osteoporosis	1.54e-05	0.00163	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—OXCT1—osteoporosis	1.54e-05	0.00163	CbGpPWpGaD
Paricalcitol—Confusional state—Zoledronate—osteoporosis	1.54e-05	0.000504	CcSEcCtD
Paricalcitol—Hypersensitivity—Calcitriol—osteoporosis	1.54e-05	0.000503	CcSEcCtD
Paricalcitol—Cardiac disorder—Estradiol—osteoporosis	1.53e-05	0.000503	CcSEcCtD
Paricalcitol—Arthralgia—Conjugated Estrogens—osteoporosis	1.53e-05	0.000502	CcSEcCtD
Paricalcitol—Chest pain—Conjugated Estrogens—osteoporosis	1.53e-05	0.000502	CcSEcCtD
Paricalcitol—Myalgia—Conjugated Estrogens—osteoporosis	1.53e-05	0.000502	CcSEcCtD
Paricalcitol—Asthenia—Ibandronate—osteoporosis	1.53e-05	0.000501	CcSEcCtD
Paricalcitol—Anxiety—Conjugated Estrogens—osteoporosis	1.53e-05	0.0005	CcSEcCtD
Paricalcitol—Nausea—Etidronic acid—osteoporosis	1.52e-05	0.0005	CcSEcCtD
Paricalcitol—Oedema—Zoledronate—osteoporosis	1.52e-05	0.0005	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	1.52e-05	0.000498	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Pamidronate—osteoporosis	1.52e-05	0.000498	CcSEcCtD
Paricalcitol—Diarrhoea—Estropipate—osteoporosis	1.52e-05	0.000498	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Risedronate—osteoporosis	1.52e-05	0.000497	CcSEcCtD
Paricalcitol—Infection—Zoledronate—osteoporosis	1.51e-05	0.000496	CcSEcCtD
Paricalcitol—Fatigue—Risedronate—osteoporosis	1.51e-05	0.000496	CcSEcCtD
Paricalcitol—Insomnia—Pamidronate—osteoporosis	1.51e-05	0.000495	CcSEcCtD
Paricalcitol—Pruritus—Ibandronate—osteoporosis	1.51e-05	0.000494	CcSEcCtD
Paricalcitol—Constipation—Risedronate—osteoporosis	1.5e-05	0.000492	CcSEcCtD
Paricalcitol—Pain—Risedronate—osteoporosis	1.5e-05	0.000492	CcSEcCtD
Paricalcitol—Angiopathy—Estradiol—osteoporosis	1.5e-05	0.000492	CcSEcCtD
Paricalcitol—Shock—Zoledronate—osteoporosis	1.5e-05	0.000491	CcSEcCtD
Paricalcitol—Paraesthesia—Pamidronate—osteoporosis	1.5e-05	0.000491	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—MGLL—osteoporosis	1.5e-05	0.00159	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP27A1—osteoporosis	1.5e-05	0.00159	CbGpPWpGaD
Paricalcitol—Diarrhoea—Alendronate—osteoporosis	1.5e-05	0.000491	CcSEcCtD
Paricalcitol—Asthenia—Calcitriol—osteoporosis	1.5e-05	0.00049	CcSEcCtD
Paricalcitol—Nervous system disorder—Zoledronate—osteoporosis	1.49e-05	0.00049	CcSEcCtD
Paricalcitol—Immune system disorder—Estradiol—osteoporosis	1.49e-05	0.000489	CcSEcCtD
Paricalcitol—Mediastinal disorder—Estradiol—osteoporosis	1.49e-05	0.000488	CcSEcCtD
Paricalcitol—Dyspnoea—Pamidronate—osteoporosis	1.49e-05	0.000488	CcSEcCtD
Paricalcitol—Feeling abnormal—Ethinyl Estradiol—osteoporosis	1.48e-05	0.000486	CcSEcCtD
Paricalcitol—Chills—Estradiol—osteoporosis	1.48e-05	0.000486	CcSEcCtD
Paricalcitol—Somnolence—Pamidronate—osteoporosis	1.48e-05	0.000486	CcSEcCtD
Paricalcitol—Skin disorder—Zoledronate—osteoporosis	1.48e-05	0.000485	CcSEcCtD
Paricalcitol—Pruritus—Calcitriol—osteoporosis	1.47e-05	0.000483	CcSEcCtD
Paricalcitol—Hyperhidrosis—Zoledronate—osteoporosis	1.47e-05	0.000483	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	1.47e-05	0.000482	CcSEcCtD
Paricalcitol—Diarrhoea—Raloxifene—osteoporosis	1.47e-05	0.000482	CcSEcCtD
Paricalcitol—Dyspepsia—Pamidronate—osteoporosis	1.47e-05	0.000481	CcSEcCtD
Paricalcitol—Dizziness—Estropipate—osteoporosis	1.47e-05	0.000481	CcSEcCtD
Paricalcitol—Oedema—Conjugated Estrogens—osteoporosis	1.47e-05	0.000481	CcSEcCtD
Paricalcitol—Alopecia—Estradiol—osteoporosis	1.46e-05	0.000479	CcSEcCtD
Paricalcitol—Infection—Conjugated Estrogens—osteoporosis	1.46e-05	0.000478	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ACP5—osteoporosis	1.46e-05	0.00154	CbGpPWpGaD
Paricalcitol—Diarrhoea—Ibandronate—osteoporosis	1.46e-05	0.000478	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—TGFB1—osteoporosis	1.45e-05	0.00154	CbGpPWpGaD
Paricalcitol—Anorexia—Zoledronate—osteoporosis	1.45e-05	0.000476	CcSEcCtD
Paricalcitol—Decreased appetite—Pamidronate—osteoporosis	1.45e-05	0.000475	CcSEcCtD
Paricalcitol—Mental disorder—Estradiol—osteoporosis	1.45e-05	0.000475	CcSEcCtD
Paricalcitol—Dizziness—Alendronate—osteoporosis	1.45e-05	0.000474	CcSEcCtD
Paricalcitol—Shock—Conjugated Estrogens—osteoporosis	1.44e-05	0.000473	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Pamidronate—osteoporosis	1.44e-05	0.000472	CcSEcCtD
Paricalcitol—Nervous system disorder—Conjugated Estrogens—osteoporosis	1.44e-05	0.000472	CcSEcCtD
Paricalcitol—Malnutrition—Estradiol—osteoporosis	1.44e-05	0.000472	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.44e-05	0.00152	CbGpPWpGaD
Paricalcitol—Fatigue—Pamidronate—osteoporosis	1.44e-05	0.000471	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Risedronate—osteoporosis	1.44e-05	0.00047	CcSEcCtD
Paricalcitol—Urticaria—Ethinyl Estradiol—osteoporosis	1.43e-05	0.000469	CcSEcCtD
Paricalcitol—Constipation—Pamidronate—osteoporosis	1.43e-05	0.000468	CcSEcCtD
Paricalcitol—Pain—Pamidronate—osteoporosis	1.43e-05	0.000468	CcSEcCtD
Paricalcitol—Diarrhoea—Calcitriol—osteoporosis	1.43e-05	0.000468	CcSEcCtD
Paricalcitol—Skin disorder—Conjugated Estrogens—osteoporosis	1.43e-05	0.000467	CcSEcCtD
Paricalcitol—Hypotension—Zoledronate—osteoporosis	1.42e-05	0.000467	CcSEcCtD
Paricalcitol—Abdominal pain—Ethinyl Estradiol—osteoporosis	1.42e-05	0.000466	CcSEcCtD
Paricalcitol—Body temperature increased—Ethinyl Estradiol—osteoporosis	1.42e-05	0.000466	CcSEcCtD
Paricalcitol—Dizziness—Raloxifene—osteoporosis	1.42e-05	0.000466	CcSEcCtD
Paricalcitol—Hyperhidrosis—Conjugated Estrogens—osteoporosis	1.42e-05	0.000465	CcSEcCtD
Paricalcitol—Tension—Estradiol—osteoporosis	1.41e-05	0.000463	CcSEcCtD
Paricalcitol—Vomiting—Estropipate—osteoporosis	1.41e-05	0.000463	CcSEcCtD
Paricalcitol—Dysgeusia—Estradiol—osteoporosis	1.41e-05	0.000462	CcSEcCtD
Paricalcitol—Dizziness—Ibandronate—osteoporosis	1.41e-05	0.000462	CcSEcCtD
Paricalcitol—Rash—Estropipate—osteoporosis	1.4e-05	0.000459	CcSEcCtD
Paricalcitol—Dermatitis—Estropipate—osteoporosis	1.4e-05	0.000459	CcSEcCtD
Paricalcitol—Anorexia—Conjugated Estrogens—osteoporosis	1.4e-05	0.000458	CcSEcCtD
Paricalcitol—Nervousness—Estradiol—osteoporosis	1.4e-05	0.000458	CcSEcCtD
Paricalcitol—Urticaria—Risedronate—osteoporosis	1.39e-05	0.000457	CcSEcCtD
Paricalcitol—Back pain—Estradiol—osteoporosis	1.39e-05	0.000456	CcSEcCtD
Paricalcitol—Headache—Estropipate—osteoporosis	1.39e-05	0.000456	CcSEcCtD
Paricalcitol—Vomiting—Alendronate—osteoporosis	1.39e-05	0.000456	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Zoledronate—osteoporosis	1.39e-05	0.000455	CcSEcCtD
Paricalcitol—Body temperature increased—Risedronate—osteoporosis	1.39e-05	0.000455	CcSEcCtD
Paricalcitol—Abdominal pain—Risedronate—osteoporosis	1.39e-05	0.000455	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	1.39e-05	0.00147	CbGpPWpGaD
Paricalcitol—Muscle spasms—Estradiol—osteoporosis	1.38e-05	0.000453	CcSEcCtD
Paricalcitol—Rash—Alendronate—osteoporosis	1.38e-05	0.000452	CcSEcCtD
Paricalcitol—Insomnia—Zoledronate—osteoporosis	1.38e-05	0.000452	CcSEcCtD
Paricalcitol—Dermatitis—Alendronate—osteoporosis	1.38e-05	0.000452	CcSEcCtD
Paricalcitol—Feeling abnormal—Pamidronate—osteoporosis	1.37e-05	0.000451	CcSEcCtD
Paricalcitol—Hypotension—Conjugated Estrogens—osteoporosis	1.37e-05	0.000449	CcSEcCtD
Paricalcitol—Headache—Alendronate—osteoporosis	1.37e-05	0.000449	CcSEcCtD
Paricalcitol—Paraesthesia—Zoledronate—osteoporosis	1.37e-05	0.000449	CcSEcCtD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	1.37e-05	0.00145	CbGpPWpGaD
Paricalcitol—Vomiting—Raloxifene—osteoporosis	1.37e-05	0.000448	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Pamidronate—osteoporosis	1.36e-05	0.000447	CcSEcCtD
Paricalcitol—Dyspnoea—Zoledronate—osteoporosis	1.36e-05	0.000445	CcSEcCtD
Paricalcitol—Rash—Raloxifene—osteoporosis	1.36e-05	0.000445	CcSEcCtD
Paricalcitol—Dermatitis—Raloxifene—osteoporosis	1.36e-05	0.000444	CcSEcCtD
Paricalcitol—Somnolence—Zoledronate—osteoporosis	1.35e-05	0.000444	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—TPI1—osteoporosis	1.35e-05	0.00143	CbGpPWpGaD
Paricalcitol—Vomiting—Ibandronate—osteoporosis	1.35e-05	0.000444	CcSEcCtD
Paricalcitol—Headache—Raloxifene—osteoporosis	1.35e-05	0.000442	CcSEcCtD
Paricalcitol—Rash—Ibandronate—osteoporosis	1.34e-05	0.00044	CcSEcCtD
Paricalcitol—Dermatitis—Ibandronate—osteoporosis	1.34e-05	0.00044	CcSEcCtD
Paricalcitol—Dyspepsia—Zoledronate—osteoporosis	1.34e-05	0.00044	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	1.34e-05	0.000438	CcSEcCtD
Paricalcitol—Ill-defined disorder—Estradiol—osteoporosis	1.34e-05	0.000438	CcSEcCtD
Paricalcitol—Headache—Ibandronate—osteoporosis	1.33e-05	0.000437	CcSEcCtD
Paricalcitol—Insomnia—Conjugated Estrogens—osteoporosis	1.33e-05	0.000435	CcSEcCtD
Paricalcitol—Hypersensitivity—Ethinyl Estradiol—osteoporosis	1.33e-05	0.000435	CcSEcCtD
Paricalcitol—Vomiting—Calcitriol—osteoporosis	1.33e-05	0.000434	CcSEcCtD
Paricalcitol—Decreased appetite—Zoledronate—osteoporosis	1.32e-05	0.000434	CcSEcCtD
Paricalcitol—Agitation—Estradiol—osteoporosis	1.32e-05	0.000433	CcSEcCtD
Paricalcitol—Nausea—Estropipate—osteoporosis	1.32e-05	0.000432	CcSEcCtD
Paricalcitol—Abdominal pain—Pamidronate—osteoporosis	1.32e-05	0.000432	CcSEcCtD
Paricalcitol—Body temperature increased—Pamidronate—osteoporosis	1.32e-05	0.000432	CcSEcCtD
Paricalcitol—Paraesthesia—Conjugated Estrogens—osteoporosis	1.32e-05	0.000432	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Zoledronate—osteoporosis	1.32e-05	0.000431	CcSEcCtD
Paricalcitol—Angioedema—Estradiol—osteoporosis	1.31e-05	0.000431	CcSEcCtD
Paricalcitol—Rash—Calcitriol—osteoporosis	1.31e-05	0.000431	CcSEcCtD
Paricalcitol—Fatigue—Zoledronate—osteoporosis	1.31e-05	0.000431	CcSEcCtD
Paricalcitol—Dermatitis—Calcitriol—osteoporosis	1.31e-05	0.00043	CcSEcCtD
Paricalcitol—Dyspnoea—Conjugated Estrogens—osteoporosis	1.31e-05	0.000429	CcSEcCtD
Paricalcitol—Headache—Calcitriol—osteoporosis	1.31e-05	0.000428	CcSEcCtD
Paricalcitol—Somnolence—Conjugated Estrogens—osteoporosis	1.3e-05	0.000428	CcSEcCtD
Paricalcitol—Pain—Zoledronate—osteoporosis	1.3e-05	0.000427	CcSEcCtD
Paricalcitol—Constipation—Zoledronate—osteoporosis	1.3e-05	0.000427	CcSEcCtD
Paricalcitol—Nausea—Alendronate—osteoporosis	1.3e-05	0.000426	CcSEcCtD
Paricalcitol—Malaise—Estradiol—osteoporosis	1.3e-05	0.000425	CcSEcCtD
Paricalcitol—Hypersensitivity—Risedronate—osteoporosis	1.29e-05	0.000424	CcSEcCtD
Paricalcitol—Vertigo—Estradiol—osteoporosis	1.29e-05	0.000424	CcSEcCtD
Paricalcitol—Dyspepsia—Conjugated Estrogens—osteoporosis	1.29e-05	0.000423	CcSEcCtD
Paricalcitol—Asthenia—Ethinyl Estradiol—osteoporosis	1.29e-05	0.000423	CcSEcCtD
Paricalcitol—Syncope—Estradiol—osteoporosis	1.29e-05	0.000423	CcSEcCtD
Paricalcitol—Nausea—Raloxifene—osteoporosis	1.28e-05	0.000419	CcSEcCtD
Paricalcitol—Decreased appetite—Conjugated Estrogens—osteoporosis	1.28e-05	0.000418	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—P4HB—osteoporosis	1.27e-05	0.00135	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—IDH2—osteoporosis	1.27e-05	0.00135	CbGpPWpGaD
Paricalcitol—Pruritus—Ethinyl Estradiol—osteoporosis	1.27e-05	0.000417	CcSEcCtD
Paricalcitol—Palpitations—Estradiol—osteoporosis	1.27e-05	0.000417	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	1.27e-05	0.000415	CcSEcCtD
Paricalcitol—Fatigue—Conjugated Estrogens—osteoporosis	1.27e-05	0.000415	CcSEcCtD
Paricalcitol—Nausea—Ibandronate—osteoporosis	1.26e-05	0.000415	CcSEcCtD
Paricalcitol—Loss of consciousness—Estradiol—osteoporosis	1.26e-05	0.000415	CcSEcCtD
Paricalcitol—Asthenia—Risedronate—osteoporosis	1.26e-05	0.000413	CcSEcCtD
Paricalcitol—Feeling abnormal—Zoledronate—osteoporosis	1.26e-05	0.000412	CcSEcCtD
Paricalcitol—Cough—Estradiol—osteoporosis	1.26e-05	0.000412	CcSEcCtD
Paricalcitol—Pain—Conjugated Estrogens—osteoporosis	1.25e-05	0.000411	CcSEcCtD
Paricalcitol—Constipation—Conjugated Estrogens—osteoporosis	1.25e-05	0.000411	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GAPDH—osteoporosis	1.25e-05	0.00132	CbGpPWpGaD
Paricalcitol—Gastrointestinal pain—Zoledronate—osteoporosis	1.25e-05	0.000408	CcSEcCtD
Paricalcitol—Hypertension—Estradiol—osteoporosis	1.24e-05	0.000407	CcSEcCtD
Paricalcitol—Pruritus—Risedronate—osteoporosis	1.24e-05	0.000407	CcSEcCtD
Paricalcitol—Nausea—Calcitriol—osteoporosis	1.24e-05	0.000406	CcSEcCtD
Paricalcitol—Diarrhoea—Ethinyl Estradiol—osteoporosis	1.23e-05	0.000404	CcSEcCtD
Paricalcitol—Hypersensitivity—Pamidronate—osteoporosis	1.23e-05	0.000403	CcSEcCtD
Paricalcitol—Arthralgia—Estradiol—osteoporosis	1.23e-05	0.000402	CcSEcCtD
Paricalcitol—Myalgia—Estradiol—osteoporosis	1.23e-05	0.000402	CcSEcCtD
Paricalcitol—Chest pain—Estradiol—osteoporosis	1.23e-05	0.000402	CcSEcCtD
Paricalcitol—Anxiety—Estradiol—osteoporosis	1.22e-05	0.0004	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—RAP1A—osteoporosis	1.22e-05	0.00129	CbGpPWpGaD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	1.22e-05	0.000399	CcSEcCtD
Paricalcitol—Urticaria—Zoledronate—osteoporosis	1.21e-05	0.000397	CcSEcCtD
Paricalcitol—Discomfort—Estradiol—osteoporosis	1.21e-05	0.000397	CcSEcCtD
Paricalcitol—Abdominal pain—Zoledronate—osteoporosis	1.2e-05	0.000395	CcSEcCtD
Paricalcitol—Body temperature increased—Zoledronate—osteoporosis	1.2e-05	0.000395	CcSEcCtD
Paricalcitol—Diarrhoea—Risedronate—osteoporosis	1.2e-05	0.000394	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	1.2e-05	0.000393	CcSEcCtD
Paricalcitol—Dry mouth—Estradiol—osteoporosis	1.2e-05	0.000393	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CYP27A1—osteoporosis	1.2e-05	0.00127	CbGpPWpGaD
Paricalcitol—Asthenia—Pamidronate—osteoporosis	1.2e-05	0.000392	CcSEcCtD
Paricalcitol—Dizziness—Ethinyl Estradiol—osteoporosis	1.19e-05	0.00039	CcSEcCtD
Paricalcitol—Confusional state—Estradiol—osteoporosis	1.18e-05	0.000388	CcSEcCtD
Paricalcitol—Pruritus—Pamidronate—osteoporosis	1.18e-05	0.000387	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—ESR1—osteoporosis	1.18e-05	0.00124	CbGpPWpGaD
Paricalcitol—Oedema—Estradiol—osteoporosis	1.17e-05	0.000385	CcSEcCtD
Paricalcitol—Infection—Estradiol—osteoporosis	1.17e-05	0.000382	CcSEcCtD
Paricalcitol—Urticaria—Conjugated Estrogens—osteoporosis	1.17e-05	0.000382	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ACP5—osteoporosis	1.16e-05	0.00123	CbGpPWpGaD
Paricalcitol—Dizziness—Risedronate—osteoporosis	1.16e-05	0.00038	CcSEcCtD
Paricalcitol—Abdominal pain—Conjugated Estrogens—osteoporosis	1.16e-05	0.00038	CcSEcCtD
Paricalcitol—Body temperature increased—Conjugated Estrogens—osteoporosis	1.16e-05	0.00038	CcSEcCtD
Paricalcitol—Shock—Estradiol—osteoporosis	1.16e-05	0.000379	CcSEcCtD
Paricalcitol—Nervous system disorder—Estradiol—osteoporosis	1.15e-05	0.000378	CcSEcCtD
Paricalcitol—Vomiting—Ethinyl Estradiol—osteoporosis	1.14e-05	0.000375	CcSEcCtD
Paricalcitol—Diarrhoea—Pamidronate—osteoporosis	1.14e-05	0.000374	CcSEcCtD
Paricalcitol—Skin disorder—Estradiol—osteoporosis	1.14e-05	0.000374	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	1.14e-05	0.0012	CbGpPWpGaD
Paricalcitol—Hyperhidrosis—Estradiol—osteoporosis	1.14e-05	0.000372	CcSEcCtD
Paricalcitol—Rash—Ethinyl Estradiol—osteoporosis	1.13e-05	0.000372	CcSEcCtD
Paricalcitol—Dermatitis—Ethinyl Estradiol—osteoporosis	1.13e-05	0.000372	CcSEcCtD
Paricalcitol—Headache—Ethinyl Estradiol—osteoporosis	1.13e-05	0.00037	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	1.12e-05	0.00119	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Zoledronate—osteoporosis	1.12e-05	0.000368	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	1.12e-05	0.00119	CbGpPWpGaD
Paricalcitol—Vomiting—Risedronate—osteoporosis	1.12e-05	0.000366	CcSEcCtD
Paricalcitol—Rash—Risedronate—osteoporosis	1.11e-05	0.000363	CcSEcCtD
Paricalcitol—Dermatitis—Risedronate—osteoporosis	1.11e-05	0.000362	CcSEcCtD
Paricalcitol—Dizziness—Pamidronate—osteoporosis	1.1e-05	0.000362	CcSEcCtD
Paricalcitol—Headache—Risedronate—osteoporosis	1.1e-05	0.00036	CcSEcCtD
Paricalcitol—Asthenia—Zoledronate—osteoporosis	1.09e-05	0.000358	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—TPI1—osteoporosis	1.08e-05	0.00115	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Conjugated Estrogens—osteoporosis	1.08e-05	0.000354	CcSEcCtD
Paricalcitol—Pruritus—Zoledronate—osteoporosis	1.08e-05	0.000353	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Estradiol—osteoporosis	1.07e-05	0.000351	CcSEcCtD
Paricalcitol—Nausea—Ethinyl Estradiol—osteoporosis	1.07e-05	0.00035	CcSEcCtD
Paricalcitol—Insomnia—Estradiol—osteoporosis	1.06e-05	0.000348	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.06e-05	0.00112	CbGpPWpGaD
Paricalcitol—Vomiting—Pamidronate—osteoporosis	1.06e-05	0.000348	CcSEcCtD
Paricalcitol—Paraesthesia—Estradiol—osteoporosis	1.05e-05	0.000346	CcSEcCtD
Paricalcitol—Asthenia—Conjugated Estrogens—osteoporosis	1.05e-05	0.000345	CcSEcCtD
Paricalcitol—Rash—Pamidronate—osteoporosis	1.05e-05	0.000345	CcSEcCtD
Paricalcitol—Dermatitis—Pamidronate—osteoporosis	1.05e-05	0.000344	CcSEcCtD
Paricalcitol—Dyspnoea—Estradiol—osteoporosis	1.05e-05	0.000343	CcSEcCtD
Paricalcitol—VDR—Gene Expression—PSMA5—osteoporosis	1.05e-05	0.00111	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PSMA2—osteoporosis	1.05e-05	0.00111	CbGpPWpGaD
Paricalcitol—Headache—Pamidronate—osteoporosis	1.05e-05	0.000343	CcSEcCtD
Paricalcitol—Somnolence—Estradiol—osteoporosis	1.04e-05	0.000342	CcSEcCtD
Paricalcitol—Diarrhoea—Zoledronate—osteoporosis	1.04e-05	0.000342	CcSEcCtD
Paricalcitol—Nausea—Risedronate—osteoporosis	1.04e-05	0.000342	CcSEcCtD
Paricalcitol—Pruritus—Conjugated Estrogens—osteoporosis	1.04e-05	0.00034	CcSEcCtD
Paricalcitol—Dyspepsia—Estradiol—osteoporosis	1.03e-05	0.000339	CcSEcCtD
Paricalcitol—Decreased appetite—Estradiol—osteoporosis	1.02e-05	0.000335	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—P4HB—osteoporosis	1.02e-05	0.00108	CbGpPWpGaD
Paricalcitol—Gastrointestinal disorder—Estradiol—osteoporosis	1.01e-05	0.000332	CcSEcCtD
Paricalcitol—Fatigue—Estradiol—osteoporosis	1.01e-05	0.000332	CcSEcCtD
Paricalcitol—Dizziness—Zoledronate—osteoporosis	1.01e-05	0.00033	CcSEcCtD
Paricalcitol—Constipation—Estradiol—osteoporosis	1e-05	0.000329	CcSEcCtD
Paricalcitol—Pain—Estradiol—osteoporosis	1e-05	0.000329	CcSEcCtD
Paricalcitol—Diarrhoea—Conjugated Estrogens—osteoporosis	1e-05	0.000329	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GAPDH—osteoporosis	9.99e-06	0.00106	CbGpPWpGaD
Paricalcitol—Nausea—Pamidronate—osteoporosis	9.91e-06	0.000325	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ENO1—osteoporosis	9.84e-06	0.00104	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—RAP1A—osteoporosis	9.73e-06	0.00103	CbGpPWpGaD
Paricalcitol—Dizziness—Conjugated Estrogens—osteoporosis	9.7e-06	0.000318	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—PSMA2—osteoporosis	9.7e-06	0.00103	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PSMA5—osteoporosis	9.7e-06	0.00103	CbGpPWpGaD
Paricalcitol—Vomiting—Zoledronate—osteoporosis	9.69e-06	0.000318	CcSEcCtD
Paricalcitol—Feeling abnormal—Estradiol—osteoporosis	9.68e-06	0.000317	CcSEcCtD
Paricalcitol—Rash—Zoledronate—osteoporosis	9.61e-06	0.000315	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Estradiol—osteoporosis	9.6e-06	0.000315	CcSEcCtD
Paricalcitol—Dermatitis—Zoledronate—osteoporosis	9.6e-06	0.000315	CcSEcCtD
Paricalcitol—Headache—Zoledronate—osteoporosis	9.55e-06	0.000313	CcSEcCtD
Paricalcitol—VDR—Gene Expression—ESR2—osteoporosis	9.34e-06	0.000988	CbGpPWpGaD
Paricalcitol—Vomiting—Conjugated Estrogens—osteoporosis	9.33e-06	0.000306	CcSEcCtD
Paricalcitol—Urticaria—Estradiol—osteoporosis	9.33e-06	0.000306	CcSEcCtD
Paricalcitol—Abdominal pain—Estradiol—osteoporosis	9.28e-06	0.000304	CcSEcCtD
Paricalcitol—Body temperature increased—Estradiol—osteoporosis	9.28e-06	0.000304	CcSEcCtD
Paricalcitol—Rash—Conjugated Estrogens—osteoporosis	9.25e-06	0.000303	CcSEcCtD
Paricalcitol—Dermatitis—Conjugated Estrogens—osteoporosis	9.24e-06	0.000303	CcSEcCtD
Paricalcitol—Headache—Conjugated Estrogens—osteoporosis	9.19e-06	0.000301	CcSEcCtD
Paricalcitol—Nausea—Zoledronate—osteoporosis	9.05e-06	0.000297	CcSEcCtD
Paricalcitol—Nausea—Conjugated Estrogens—osteoporosis	8.72e-06	0.000286	CcSEcCtD
Paricalcitol—Hypersensitivity—Estradiol—osteoporosis	8.65e-06	0.000284	CcSEcCtD
Paricalcitol—Asthenia—Estradiol—osteoporosis	8.43e-06	0.000276	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	8.33e-06	0.000882	CbGpPWpGaD
Paricalcitol—Pruritus—Estradiol—osteoporosis	8.31e-06	0.000272	CcSEcCtD
Paricalcitol—Diarrhoea—Estradiol—osteoporosis	8.04e-06	0.000263	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CYP19A1—osteoporosis	7.87e-06	0.000833	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ENO1—osteoporosis	7.87e-06	0.000833	CbGpPWpGaD
Paricalcitol—Dizziness—Estradiol—osteoporosis	7.77e-06	0.000255	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—PSMA2—osteoporosis	7.75e-06	0.000821	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PSMA5—osteoporosis	7.75e-06	0.000821	CbGpPWpGaD
Paricalcitol—Vomiting—Estradiol—osteoporosis	7.47e-06	0.000245	CcSEcCtD
Paricalcitol—Rash—Estradiol—osteoporosis	7.4e-06	0.000243	CcSEcCtD
Paricalcitol—Dermatitis—Estradiol—osteoporosis	7.4e-06	0.000242	CcSEcCtD
Paricalcitol—Headache—Estradiol—osteoporosis	7.36e-06	0.000241	CcSEcCtD
Paricalcitol—Nausea—Estradiol—osteoporosis	6.98e-06	0.000229	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	6.76e-06	0.000715	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ADCY5—osteoporosis	6.43e-06	0.00068	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GPX1—osteoporosis	6.41e-06	0.000678	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP19A1—osteoporosis	6.29e-06	0.000666	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—MYC—osteoporosis	6.12e-06	0.000648	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	5.97e-06	0.000632	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—MTHFR—osteoporosis	5.91e-06	0.000626	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	5.89e-06	0.000623	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ESR1—osteoporosis	5.66e-06	0.000599	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ADCY5—osteoporosis	5.14e-06	0.000544	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GPX1—osteoporosis	5.12e-06	0.000542	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—POMC—osteoporosis	4.73e-06	0.0005	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—MTHFR—osteoporosis	4.73e-06	0.0005	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—POMC—osteoporosis	3.78e-06	0.0004	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—POMC—osteoporosis	3.59e-06	0.00038	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PKM—osteoporosis	3.38e-06	0.000358	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—FDPS—osteoporosis	3.38e-06	0.000358	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GPD2—osteoporosis	3.21e-06	0.00034	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PGLS—osteoporosis	3.21e-06	0.00034	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MYC—osteoporosis	2.95e-06	0.000312	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PNP—osteoporosis	2.93e-06	0.000311	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ATIC—osteoporosis	2.93e-06	0.000311	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CA2—osteoporosis	2.5e-06	0.000264	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—OXCT1—osteoporosis	2.5e-06	0.000264	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MGLL—osteoporosis	2.43e-06	0.000257	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—IDH2—osteoporosis	2.07e-06	0.000219	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.94e-06	0.000206	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ACP5—osteoporosis	1.89e-06	0.0002	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TPI1—osteoporosis	1.76e-06	0.000186	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—P4HB—osteoporosis	1.65e-06	0.000175	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GAPDH—osteoporosis	1.62e-06	0.000172	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—RAP1A—osteoporosis	1.58e-06	0.000167	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ENO1—osteoporosis	1.28e-06	0.000135	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PSMA5—osteoporosis	1.26e-06	0.000133	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PSMA2—osteoporosis	1.26e-06	0.000133	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.02e-06	0.000108	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ADCY5—osteoporosis	8.34e-07	8.83e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GPX1—osteoporosis	8.31e-07	8.8e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MTHFR—osteoporosis	7.67e-07	8.12e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—POMC—osteoporosis	6.14e-07	6.49e-05	CbGpPWpGaD
